AbbVie: Strong Data, Once Daily Dose ‘Necessary to Ensure Strong Commercial Success’

Shares of AbbVie (ABBV) have jumped today after a rheumatoid arthritis treatment that it’s developing with Galapagos (GLPYY) appeared to perform well in a drug trial. Credit Suisse analysts Vamil Divan and Ari Jahja have the details: brendan mcdermid/Reuters AbbVie’s partner Galapagos NV released positive data after the close from the first phase 2b study [...]